A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus

Hepatology International

Volumn 10, Issue 6, 2016, Pages 947-955

  Lim, Young Suk ^a   Ahn, Sang Hoon ^b   Lee, Kwan Sik ^c   Paik, Seung Woon ^d   Lee, Youn Jae ^e   Jeong, Sook Hyang ^f   Kim, Ju Hyun ^g   Yoon, Seung Kew ^h   Yim, Hyung Joon ⁱ   Tak, Won Young ^j   Han, Sang Young ^k   Yang, Jenny C ^l   Mo, Hongmei ^l   Garrison, Kimberly L ^l   Gao, Bing ^l   Knox, Steven J ^l   Pang, Phillip S ^l   Kim, Yoon Jun ^m   Byun, Kwan Soo ⁿ   Kim, Young Seok ^o   Heo, Jeong ^p   Han, Kwang Hyub ^b   more..

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Seoul National University Bundang Hospital   (South Korea)

^g Gachon University College of Medicine   (South Korea)

^h The Catholic University of Korea   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j Kyungpook National University Hospital   (South Korea)

^k Dong A University   (South Korea)

^l GILEAD SCIENCES   (United States)

^m Seoul National University Hospital   (South Korea)

ⁿ Korea University College of Medicine   (South Korea)

^o Soonchunhyang University   (South Korea)

^p Pusan National University Hospital   (South Korea)

more..

Author keywords

Genotype 1; Hepatitis C virus (HCV); Korea; Ledipasvir; Sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; ADVERSE OUTCOME; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; HEPACIVIRUS; MIDDLE AGED; SOUTH KOREA; SUSTAINED VIROLOGIC RESPONSE; TABLET; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; REPUBLIC OF KOREA; SUSTAINED VIROLOGIC RESPONSE; TABLETS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84969792629     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-016-9726-5     Document Type: Article

References (36)

1. Lim YS. Current status of liver disease in Korea: hepatitis C. Korean J Hepatol 2009;15(Suppl 6):S25–S28
2. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681–688
3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–115
4. Kim do Y, Kim IH, Jeong SH, et al. A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int 2013;33:586–594
5. Oh DJ, Park YM, Seo YI, Lee JS, Lee JY. Prevalence of hepatitis C virus infections and distribution of hepatitis C virus genotypes among Korean blood donors. Ann Lab Med 2012;32:210–215
6. Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin Mol Hepatol 2012;18:219–224
7. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2014;20:89–136
8. Park SY, Rim MY, Yo IK, et al. [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis]. Korean J Gastroenterol 2012;60:306–314
9. Conjeevaram HS, Fried MW, Jeffers LJ, Virahep-C Study Group, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470–477
10. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265–2271
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965
12. Hadziyannis SJ, Sette H Jr, Morgan TR, PEGASYS International Study Group, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355
13. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 2009;81:2029–2035
14. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954–960
15. Nicot F, Alric L, Barange K, et al. Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol 2011;83:437–444.
16. Lyoo K, Song MJ, Hur W, et al. Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin. J Clin Virol 2011;52:363–366
17. Jung YK, Kim JH, Ahn SM, et al. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans. J Clin Gastroenterol 2013;47:644–650
18. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801
19. Kim SU, Song KJ, Chang HY, et al. Association between IL28B polymorphisms and spontaneous clearance of hepatitis B virus infection. PLoS ONE 2013;8:e69166
20. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982
21. Höroldt B, Haydon G, O’Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int 2006;26:650–659.
22. Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719–728
23. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 2010;201:751–759
24. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006;101:1260–1267
25. Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006;20:589–592
26. Marcus EL, Tur-Kaspa R. Chronic hepatitis C virus infection in older adults. Clin Infect Dis 2005;41:1606–1612
27. Gilead Sciences, Inc. HARVONI (ledipasvir and sofosbuvir) prescribing information. Foster City: Gilead Sciences, Inc.; 2014.
28. Gilead Sciences International Ltd. HARVONI (ledipasvir/sofosbuvir) summary of product characteristics. Cambridge: Gilead Sciences International Ltd.; 2014
29. Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–1898
30. Kowdley KV, Gordon SC, Reddy KR, et al. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888
31. Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–1493
32. Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645–653
33. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
34. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404–413
35. García-Samaniego J, Romero M, Granados R, et al. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol 2013;19:1943–1952
36. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639–644